A Phase 1b/2 Study of Hypofractionated Radiation and Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Trial Profile

A Phase 1b/2 Study of Hypofractionated Radiation and Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Interleukin-2 (Primary) ; Ipilimumab (Primary)
  • Indications Brain metastases; Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top